This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients.
In this video, Michael B. Atkins, MD, of Georgetown University in Washington, DC, discusses second-line data from the IMmotion150 trial.
The study initially tested first-line atezolizumab vs sunitinib vs atezolizumab plus bevacizumab in untreated patients with metastatic renal cell carcinoma, and demonstrated an improved progression-free survival for the atezolizumab/bevacizumab combination.
Atkins presented second-line results of the study (abstract 4505) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
